You are here

Novartis gets creative in pricing next-generation cancer therapy

Its medicine is for a severe form of cancer in young people, known as acute lymphoblastic leukaemia

London

NOVARTIS AG, set to beat Kite Pharma Inc to the finish line in one of the most promising new areas of cancer research, is examining how to price a revolutionary therapy patients will need to take just once.

The US Food and Drug Administration is likely to rule in early

sentifi.com

Market voices on:

Powered by GET.comGetCom